- Date 22 June 2016
- Documents : 3
- History
- (Restricted access link)
Listen
SIMPONI, (golimumab), TNF inhibitor
RHEUMATOLOGY - New indication
Opinions on drugs -
Posted on
Sep 05 2016
Reason for request
Extension of Inclusin
No clinical benefit demonstrated by comparison with other TNF inhibitors in the management of patients with severe non-radiographic axial spondyloarthritis with objective signs of inflammation and who failed NSAIDs.
- SIMPONI now has Marketing Authorisation in the treatment of severe non-radiographic axial spondyloarthritis in adults with objectives signs of inflammation, taking the form of an elevated level of C-reactive protein (CRP) and/or signs visible in magnetic resonance imaging (MRI), in patients with an inadequate response to non-steroidal antiinflammatories (NSAIDs).
- Since no comparison is available with other TNF inhibitors indicated in non-radiographic axial spondyloarthritis, it is not possible to rank SIMPONI relative to other TNF inhibitors.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
English version
Contact Us
Évaluation des médicaments
